Affymetrix Commercializes Transcriptome Array

Affymetrix Inc announces commercialization of the next-generation human transcriptome array demonstrated by Stanford University researchers to be superior to mRNA sequencing (RNA-Seq) in gene expression profiling studies.

Abbott Receives FDA Clearance for ALK FISH Test

The new Abbott Vysis ALK Break Apart FISH Probe test is designed to identify ALK-positive NSCLC patients for Pfizer’s approved NSCLC therapy, XALKORI (crizotinib), an oral ALK inhibitor.